Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ondine Biomedical Inc. (OBI.L)
Vancouver, BC, CA
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +27.66% | +46.34% | +30.43% | +71.43% | +76.47% | -3.23% | -74.14% | -74.14% | -74.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+70.3% ★ Q2'25: +140.9% (vs Q2'23)
-
EPS growth Biotechnology: +29.7%+4.2% Q2'25: +27.9% (vs Q2'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-811.6% Q2'25: -1,006.8% (vs Q2'23)
-
EBIT margin Biotechnology: +0.0%-929.8% Q2'25: -1,235.9% (vs Q2'23)
-
ROIC Biotechnology: -16.1%— Q2'25: +1,195.4% (vs Q2'23)
-
Share dilution Biotechnology: -3.4%+39.3% Q2'25: +124.6% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q2'25: -0.01× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.57M
est: 3.28M (-21.6%)
|
638.0K
est: 587.9K (+8.5%)
|
1.20M
est: 1.39M (-13.5%)
|
2.05M
est: 2.80M (-26.8%)
|
4.89M
est.
|
12.12M
12.12M – 12.12M
+147.9% YoY
|
34.96M
34.96M – 34.96M
+188.5% YoY
|
102.31M
102.31M – 102.31M
+192.6% YoY
|
268.58M
268.58M – 268.58M
+162.5% YoY
|
| EBITDA |
-48.36M
est: -3.28M (-1,375.7%)
|
-18.85M
est: -587.9K (-3,106.3%)
|
-13.79M
est: -1.39M (-891.6%)
|
-18.49M
est: -2.80M (-560.7%)
|
-4.89M
est.
|
-12.12M
-12.12M – -12.12M
-147.9% YoY
|
-34.96M
-34.96M – -34.96M
-188.5% YoY
|
-102.31M
-102.31M – -102.31M
-192.6% YoY
|
-268.58M
-268.58M – -268.58M
-162.5% YoY
|
| EBIT |
-48.87M
est: -3.28M (-1,391.3%)
|
-19.34M
est: -587.9K (-3,190.1%)
|
-14.37M
est: -1.39M (-933.8%)
|
-19.05M
est: -2.80M (-580.9%)
|
-4.89M
est.
|
-12.12M
-12.12M – -12.12M
-147.9% YoY
|
-34.96M
-34.96M – -34.96M
-188.5% YoY
|
-102.31M
-102.31M – -102.31M
-192.6% YoY
|
-268.58M
-268.58M – -268.58M
-162.5% YoY
|
| Net Income |
-50.09M
est: -55.13M (+9.1%)
|
-19.37M
est: -26.44M (+26.7%)
|
-14.41M
est: -18.05M (+20.2%)
|
-19.10M
est: -16.46M (-16.0%)
|
-16.44M
est.
|
-10.91M
-10.91M – -10.91M
+33.6% YoY
|
-2.73M
-2.73M – -2.73M
+75.0% YoY
|
5.46M
5.46M – 5.46M
+300.0% YoY
|
30.00M
30.00M – 30.00M
+450.0% YoY
|
| SGA |
13.33M
est: 29.31M (-54.5%)
|
12.31M
est: 5.26M (+134.1%)
|
9.80M
est: 12.44M (-21.2%)
|
11.01M
est: 25.03M (-56.0%)
|
43.73M
est.
|
108.39M
108.39M – 108.39M
+147.9% YoY
|
312.75M
312.75M – 312.75M
+188.5% YoY
|
915.14M
915.14M – 915.14M
+192.6% YoY
|
2.40B
2.40B – 2.40B
+162.5% YoY
|
| EPS |
-0.26
est: -0.20 (-29.5%)
|
-0.10
est: -0.10 (-3.9%)
|
-0.07
est: -0.07 (-11.2%)
|
-0.07
est: -0.06 (-16.8%)
|
-0.06
est.
|
-0.04
-0.04 – -0.04
+33.6% YoY
|
-0.01
-0.01 – -0.01
+75.0% YoY
|
0.02
0.02 – 0.02
+300.0% YoY
|
0.11
0.11 – 0.11
+450.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carolyn Cross | Founder, Chief Executive Officer & Executive Director | 890.3K | female |
| Nicolas G. Loebel | President, Chief Technology Officer & Executive Director | 714.9K | — |
| Elaine Lei | Corporate Controller & Company Secretary | — | female |
| Matt Ross | Vice President of Sales & Marketing | — | male |
| Nikita Parkev | Vice President of Finance & Company Secretary | — | male |
| Alan Thomas | Non-Board Interim Chief Financial Officer | — | male |
| William Kanz | Senior Vice President of Engineering & Operations | — | male |
| Angelika Vance | Vice President of Corporate Communications | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OBI.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
